Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1996-01-22
2000-08-22
Chan, Christina
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241841, 4241921, 42419511, 514 2, 514 8, 514885, A61K 3819
Patent
active
061068322
ABSTRACT:
There is disclosed a method of detecting a mutation in a CD40 ligand gene, comprising isolating nucleic acid from an individual, selectively amplifying nucleic acid derived from the CD40 ligand gene, and analyzing the amplified nucleic acid to determine if there is a mutation (or mutations) in the CD40 ligand gene. The ability of a CD40 ligand protein expressed from the gene may be determined. Methods of treating individuals exhibiting a defective CD40 ligand gene (i.e., X-linked hyper IgM patients and certain individuals afflicted with combined variable immunodeficiency) are also disclosed. Also disclosed are non-human animals that lack functional CD40 ligand as a result of gene targeting technology.
REFERENCES:
patent: 4873191 (1989-10-01), Wagner et al.
patent: 5474771 (1995-12-01), Lederman et al.
patent: 5540926 (1996-07-01), Aruffo et al.
patent: 5716805 (1998-02-01), Srinivasan et al.
Porst et al Clin Diag Lab Immunol. 2: 412-416 (1995).
Saiki et al. J Clin Invest. 95: 510-514 (1995).
Callard et al. Immunol. Today 14: 559-564 (1993).
Woelle et al. Immunol. Today. 13: 431-433 (1992).
Armitage et al., Nature 357:80, 1992.
Fanslow et al., J. Immunol. 149:655, 1992.
Spriggs et al., J. Exp. Med. 176:1543, 1992.
Farrah and Smith, Nature 358:26, 1992.
Noelle et al., Proc. Natl. Acad. Sci. USA 89:6550, 1992.
Hollenbaugh et al., EMBO J. 11:4313, 1992.
Allen et al., Science 259:990, 1993.
Korthauer et al., Nature 361:539, 1993.
DiSanto et al., Nature 361:541, 1993.
Aruffo et al., Cell 72:291, 1993.
Fuleihan et al., Proc. Natl. Acad. Sci. USA 90:2170, 1993.
Marx, Science 259:896, 1993.
Hill and Chapel, Nature 361:494, 1993.
Waldman, Crit. Rev. Oncol. Hematol. 12:49, 1992.
Huang, Lab. Anim. Sci. 43:156, 1993.
Koller and Smithies, Annu. Rev. Immunol. 10:705, 1992.
Joyner, Bioessays 13:649, 1991.
Smithies, Trends Genet. 9:112, 1993.
Mayer et al., New Engl. J. Med. 314:409; 1986.
Padayachee et al., Genomics 14:551; 1992.
Graf et al., Eur. J. Immunol. 22:3191; 1992.
Armitage Richard J.
Fanslow, III William C.
Spriggs Melanie K.
Widmer Michael B.
Chan Christina
Gambel Phillip
Henry Janis C.
Immunex Corporation
LandOfFree
Treatment of individuals exhibiting defective CD40L does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of individuals exhibiting defective CD40L, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of individuals exhibiting defective CD40L will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-577547